# GlobalData Plc account plan

> GlobalData is a London-listed data, analytics and AI intelligence platform serving 5,000+ clients, with 2025 revenue of £322.1m and 3,558 employees.

## At a glance

GlobalData Plc sells subscriptions to proprietary data, analytics and AI tools covering 20+ industry sectors, plus consulting, reports and events, to over 5,000 corporations, financial institutions and government organisations. Subscriptions were 74% of 2025 revenue, and the Americas are its largest market by customer location. In 2025 revenue was £322.1m (+13% reported, +1% underlying), Adjusted EBITDA £110.2m (34% margin) and profit before tax £69.2m. It had 3,558 employees at 31 December 2025, operating mainly in the UK, US and India. The shares moved to the LSE Main Market on 5 March 2026 and joined the FTSE 250 on 22 June 2026; CEO Mike Danson owned 60.8% of the ordinary shares at 30 June 2026.

## Business units

- **GlobalData Non-Healthcare** (about 62% of 2025 revenue (£198.8m)): Intelligence for Technology, Consumer, Professional & Financial Services, Industrials, Automotive and other sectors, expanded by the LinkUp, Celent, AI Palette and Stylus acquisitions. 2025 Adjusted EBITDA was £50.2m at a 25% margin, down from 33% on go-to-market investment and dilutive acquisitions. In H1 2026 revenue was £97.7m, with Consumer up 7% underlying.
- **GlobalData Healthcare** (about 38% of 2025 revenue (£123.3m)): Intelligence on drugs, devices, clinical trials and commercial healthcare data for pharmaceutical and life sciences companies, 40% owned by Inflexion since June 2024. 2025 Adjusted EBITDA was £61.8m at a 50% margin; growth came mostly from Deallus, and Cambridge Healthcare Research was acquired on 1 April 2026. Biotech weakness and US drug pricing pressure are headwinds.

## Strategic priorities

- **AI-first transformation**: A programme through to 2030 to rebuild how proprietary content is produced with AI-native workflows and human expertise; efficiency benefits are expected from the end of H2 FY26 and into FY27.
- **Retention and churn**: Lift the volume renewal rate for clients over £20,000 from 83% towards an ambition above 90%; management calls this its biggest lever for organic growth.
- **Sales transformation**: Move from product-led to solutions-led selling, with enterprise sellers, strategic account management, a revenue operations team and an inside sales team for lower-value clients.
- **End-market divisional structure**: Reorganise around customer end markets rather than product lines, with divisional management teams supported by a central operating model, following the Healthcare model.
- **Growth and margin targets**: Accelerate underlying growth to mid-single digits and recover Adjusted EBITDA margins towards 40%, though the Board now expects a more cautious recovery in margins.
- **AI Hub and data delivery**: Expand AI Hub, used by over 90% of customers, launch AI products such as Digital Workers and AVA, and serve rising demand for data feeds and APIs, including MCP integration with Microsoft 365 Copilot.

## Latest results

In the half year to 30 June 2026 revenue rose 4% reported and 1% underlying to £162.9m, with subscription revenue up 6% to 76% of the total. Adjusted EBITDA was £54.8m at a 34% margin, while profit before tax fell 6% to £23.2m as finance costs doubled to £7.7m. Net bank debt rose to £133.0m (leverage 1.2x). The value renewal rate improved to 91% while the volume renewal rate stayed at 83%. For FY26 the Board expects underlying growth towards the lower end of market expectations and Adjusted EBITDA below market expectations, with margins in line with H1.

## Investments and deals

- **Acquisitions since 2024**: Seven acquisitions since January 2024 (BTMI, LinkUp, Celent, Deallus, AI Palette, Stylus, Cambridge Healthcare) for over £132m; Cambridge Healthcare Research cost £21.3m cash plus a £0.7m loan note.
- **Shareholder returns**: Over £189m returned to shareholders since January 2024, including a £60m tender offer in September 2025 and FY26 returns of over £49m.
- **Bank facilities**: The Non-Healthcare facility was increased by £60m to £245m and the £200m Healthcare facility extended to December 2028.
- **Disposals**: Internet Business Group Limited was sold on 31 October 2025 as non-core assets were discontinued.

## Challenges and risks

- **Slow underlying growth**: Underlying revenue growth was 1% in 2025 and in H1 2026; the CEO called 2025 growth disappointing.
- **Margin pressure**: The Adjusted EBITDA margin fell from 41% to 34% in 2025 on sales investment, duplicated corporate costs and dilutive acquisitions.
- **Sales disruption**: The Chair says the sales changes had a bigger impact than expected in disruption and time to embed.
- **AI competition**: Artificial Intelligence was promoted to a principal risk at 31 December 2025, with more competitive threats from AI in existing and emerging competitors.
- **Healthcare market headwinds**: Biotech weakness and US drug pricing pressure weigh on Healthcare, whose Contracted Forward Revenue fell 1% underlying in H1 2026.

## What leadership says

> "revenue and growth remained below our ambitions and the benefits of the transformation have not yet been reflected in our financial performance. The foundations are now in place, and our focus is firmly on execution." — Mike Danson, Chief Executive, Half Year Results to 30 June 2026, 14 September 2026

> "AI is a positive theme for GlobalData" — Mike Danson, Chief Executive, Annual Report and Accounts 2025

> "Whilst we set out to deliver stronger growth, we firmly believe that the transformational changes give us the right foundation to once again deliver stronger underlying growth" — Murray Legg, Chair, Annual Report and Accounts 2025


## Where a supplier can help

- **AI content workflows**: The AI-first transformation of content production through to 2030 opens room for AI infrastructure, data engineering and workflow automation suppliers.
- **Customer success and churn reduction**: The retention priority, with volume renewal stuck at 83%, fits customer success, usage analytics and renewal management tools.
- **Sales productivity**: The sales transformation, strategic account management and inside sales team point to sales enablement, CRM and revenue operations tooling.
- **Integration of acquisitions**: Seven acquisitions since 2024 and the move to end-market divisions create integration needs in platforms, data and back-office systems.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [GlobalData Plc Annual Report and Accounts 2025](https://wp-globaldata-2023.s3.eu-west-2.amazonaws.com/media/2026/03/GlobalData-Annual-Report-2025-Final.pdf)

Annual report · 2026-03-23

- GlobalData Plc is a UK data, analytics and insights group: an "intelligence and productivity platform" combining proprietary data, human expertise and purpose-built AI on a single "One Platform", covering 20+ industry sectors for 5,000+ clients with 3,558 employees (31 Dec 2025).
- FY2025 revenue £322.1m (+13% reported, +1% underlying); operating profit £81.2m (+25%); Adjusted EBITDA £110.2m (-6%), margin 34% (2024: 41%); PBT £69.2m; subscriptions 74% of revenue.
- Two reported segments: Non-Healthcare revenue £198.8m (Adjusted EBITDA margin 25%) and Healthcare revenue £123.3m (margin 50%); 40% of Healthcare is held by Inflexion (non-controlling interest).
- Americas is the largest market (£126.8m, of which US £121.3m), then Europe £85.1m and UK £48.8m; around 60% of revenue is in currencies other than Sterling.
- 2025 was year two of the 2024-26 Growth Transformation Plan: shift from product-led to solutions-led selling with strategic account management; sales headcount 367 at 1 Jan 2026; 3 seven-figure GBP contracts signed in H2.
- AI: AI Hub passed 100,000 users, 90% of customers contracted to an AI Hub enabled product; launched Digital Workers (agentic AI) and AVA, an AI research assistant.
- M&A: AI Palette (Mar 2025) and Stylus (Jul 2025) after LinkUp, Celent and Deallus in late 2024; revenue synergies not yet realised, so Non-Healthcare M&A is de-prioritised while Healthcare keeps doing bolt-ons.
- Capital returns: £60m tender offer, £39.7m buybacks in H1 2025, a further £10m buyback from November; net bank debt £114.2m at year end (2024: net cash £10.1m).
- Targets: underlying revenue growth back to mid-single digits, Adjusted EBITDA margin recovering towards 40%; Contracted Forward Revenue £179.7m gives about 80% visibility over 2026 analyst revenue consensus.
- Governance: moved from AIM to the LSE Main Market on 5 March 2026; CFO Graham Lilley to step down, Robert Kingston (CFO of Keywords Studios, ex-Sky) to join in Q3 2026; AI is a new principal risk.

### [GlobalData Plc Half Year Results to 30 June 2026 (Interim Statement 2026)](https://wp-globaldata-2023.s3.eu-west-2.amazonaws.com/media/2026/09/Interim-Statement-2026.pdf)

Interim report · 2026-09-14

- H1 2026 (six months to 30 June 2026) revenue £162.9m, +4% reported and +1% underlying, in a market where "sales cycles elongated industry-wide".
- Adjusted EBITDA £54.8m (+5%, flat underlying), margin 34%; operating profit £30.9m; PBT down 6% to £23.2m on higher finance costs; adjusted EPS 2.7p.
- Segments: Non-Healthcare revenue £97.7m (Adjusted EBITDA margin 25%), Healthcare £65.2m (margin 48%); both grew 1% underlying. Consumer grew 7% underlying, Industrials low single digit.
- The Group is moving to an end-market divisional structure; Healthcare, with its own management team, is "the proof point". The 2024 sale of 40% of Healthcare valued the division at £1.115bn.
- AI-first internal transformation launched to rebuild content creation with AI-native workflows; AI Hub adopted by more than 90% of customers; commercial partnership with Microsoft including MCP integration with Microsoft 365 Copilot.
- Renewal rates (clients over £20k): value 91%, volume 83%; Contracted Forward Revenue £163.3m (+4%, +1% underlying).
- Capital: acquired Cambridge Healthcare Research (life sciences competitive intelligence) on 1 April 2026 for £21.3m cash; £19m of buybacks plus a £30m tender; net bank debt £133.0m; Non-Healthcare facility raised by £60m to £245m.
- Outlook cut: FY26 revenue towards the low end of consensus and Adjusted EBITDA below expectations; a "more cautious recovery" in margins towards 40% than previously stated.
- Milestones: moved to the LSE Main Market on 5 March 2026 and promoted to the FTSE 250 on 22 June 2026; Mike Danson owned 60.8% of the shares at 30 June 2026.

## Questions about GlobalData Plc

### What does GlobalData do?

GlobalData sells subscriptions to proprietary data, analytics and AI tools across 20+ industry sectors, plus consulting, reports and events, to corporations, financial institutions and governments.

### What is GlobalData's revenue?

Revenue was £322.1m in 2025, and £162.9m in the half year to 30 June 2026.

### How many employees does GlobalData have?

3,558 employees at 31 December 2025.

### What is GlobalData's strategy?

An AI-first transformation of content production, better client retention, a solutions-led sales model and an end-market divisional structure, aiming at mid-single-digit underlying growth and margins towards 40%.

### Who leads GlobalData?

Mike Danson is Chief Executive and the controlling shareholder, and Murray Legg is Chair; Robert Kingston was expected to join as CFO in Q3 2026.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
